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24S Abstracts May Supplement 2013estimates of survival at 1, 3 and 5-years were 85.8%, 81.4%
and 69.7%. Two reinterventions for endoleak were required
and no migration or late aneurysm related mortality was
recorded.
Conclusions: The incidence of stroke is acceptable
after both total and partial arch debranching. Total
debranching is an important predictor for mortality. Retro-
grade dissection may be infrequent complication with care-
ful arch approach. After the perioperative interval,
debranching is a safe and durable procedure up to 5 years.
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Objectives: Using the CHAP database of nearly
10,000 patients nationwide, we examined eligibility for
EVAR in patients with a short neck AAA (snAAA), where
the neck length < 10 mm, and identiﬁed the anatomic
parameters driving endograft (EVG) ineligibility.
Methods: Preoperative CT scans from eleven US clin-
ical sites were prospectively entered into a database from
7/96 to 11/12. A blinded third-party, M2S, recorded
standardized measurements from the 3D reconstructions.
Two currently marketed EVG in the US are labeled to treat
snAAA, with neck angulation #45 deg and neck lengthsTable. Eligibility for two marketed EVGs excluding iliac and
anatomic parameters
snAAA < 5 cm snAAA $ 5 c
M (512) W (324) M (1733) W
Cook fenestrated, % 44 44 42
Trivascular ovation, % 24 10 16
Neck length, mm 6 (3-9) 5 (2-9) 6 (2-9) 5
Neck angulation, deg 31 (16-55) 38 (18-63) 37 (18-61) 48
Neck diameter, mm 24 (26-35) 23 (18-34) 25 (20-97) 24$4 mm (Cook Fenestrated) and >7 mm (Trivascular
Ovation). The EVAR criteria were analyzed in 2245 men
(M) and 1079 women (W) with snAAA.
Results: Of the 9848 AAAs, 3324 have snAAA (34%).
Even if iliac and access criteria are excluded, EVAR eligi-
bility for snAAA is at most 45%. In snAAA >5 cm diam-
eter, neck angulation is 48 deg for women and 37 deg
for men (P < .01). Women are more likely to have neck
length < 4 mm and neck angulation > 45 deg (risk ratio
is 90). Only 6% of patients are eligible for both EVG.
Larger AAAs are not less likely to be eligible for fenestrated
EVAR (Table; P ¼ NS).
Conclusions: One-third of AAAs have a short neck,
and less than half of these are eligible for current EVG,
even with a fenestrated option. Neck angulation and length
continue to challenge EVAR eligibility, especially for
women. Eligibility for EVAR does not lessen as aneurysms
enlarge, so there is no indication for early repair.
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Video Presentation
Percutaneous Endovascular Repair of Aortoiliac
Aneurysm Using Iliac Branch Device
Mateus P. Correa, Gustavo S. Oderich. Division of Vascular
and Endovascular Surgery, Mayo Clinic, Rochester, Minn
Background: Exclusion of one or both internal iliac
arteries (IIA) during endovascular aortic aneurysm repair
(EVAR) has been associated with a predictable rate of
pelvic ischemic complications. We present the preoperative
planning and technique of implantation of Iliac Branch
Device (IBD, Cook Inc., Brisbane, Australia) in a patient
with bilateral common iliac artery (CIA) aneurysms using
total percutaneous approach.
Technical Description: Computed tomography angi-
ography (CTA) was used to determine measurementsaccess criteria; median (10th-90th percentile) values of
m snAAA > 5.5 cm snAAA > 6.5 cm
(755) M (1152) W (437) M (465) W (154)
45 45 45 45 43
7 14 6 18 3
(2-9) 6 (2 9) 5 (2-9) 5 (2 9) 4 (1-8)
(25-74) 39 (19 64) 51 (28-77) 43 (20 67) 57 (32-81)
(19-37) 25 (21 38) 24 (19-39) 26 (21 41) 24 (19-42)
Table.
Graft Type No.
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bifurcation (>16mm) and IIA (4-9mm). A right IIA
bypass was performed in a ﬁrst stage via small ﬂank incision.
For the second stage, EVAR was performed using bilateral
percutaneous femoral approach. After systemic hepariniza-
tion, a 12Fr Ansel sheath (Cook Inc., Bloomington IN)
was introduced via the right and IBD via the left femoral
approach. A guidewire was advanced via the IBD pre-
loaded catheter and snared, establishing femoral-femoral
access. The IBD was partially deployed up to the side
branch, which was opened 1-cm proximal to the CIA bifur-
cation. The 12 Fr sheath was advanced into the side
branch, followed by selective catheterization the IIA and
deployment of a 9  60 mm self-expandable stent-graft
into the IIA. The IBD was deployed into the left external
iliac artery (EIA) and kissing balloon angioplasty was per-
formed. The repair was completed by deployment of
a Cook Zenith (Bloomington IN) bifurcated stent-graft
and iliac limb extensions to connect the IBD to the left
contra-lateral gate and extend the repair to the right EIA.
Completion angiography and CTA revealed widely patency
stent-grafts with no endoleak. In conclusion, IBDs have
expanded the indications of EVAR in patients with bilateral
CIA aneurysms. The technique can be performed using
a total percutaneous approach and has the potential to
reduce rates of pelvic ischemic complications.
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Excluder 25
Zenith 17
Talent 15
Ancure 10
Powerlink 4
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The First 100 Late EVAR Explants: Largest Single
Center Experience
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Objectives: With over a decade of use of endovascular
aneurysm repair (EVAR) we have seen a rise in the number
of failing endografts. In 2007 we previously reported 41
explants and sought to re-examine our outcomes.
Methods: A retrospective analysis of EVARs requiring
late explant was performed using a database. The type of
graft, duration of implant, reason for removal, operative
technique, mortality and length of stay were reviewed.
Results: During 1999-2012, 100 patients required
explant, of which 60 were placed at an outside institution
(Table). Twenty-seven were performed in the last two years.
Ninety-one were male with an average age of 75 years
(range, 50-93 years). Grafts were excised after a median of
41 months (range, 1-144 months). Average length of stay
was 15 days (range, 1-56 days). 30 day mortality was 17%.
Elective mortality was 9.9%. There was no difference in
approach (56 retroperitoneal, 44 midline). 82% patients
had one or more endoleaks (type I, 40; II, 30; III, 22; endo-
tension, six). Migration (15), rupture (nine), aortoenteric
ﬁstula (ﬁve), infection (13), limb thrombosis (three) and
claudication (one) were also factors. Repairs were 18 tube,
66 aortoiliac, eight aorto-femoral, and seven axillo-femoral.
Twenty-two patients had partial graft excision.Conclusions: An increasing number of endografts are
being referred for removal. The overall mortality is slightly
improved to 17% from 19% in our original series despite
increased elective mortality to 9.9% from 3.3%.
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Objectives: Patients with vascular Ehlers-Danlos syn-
drome (vEDS) often present with spontaneous arterial
dissection or rupture. Mutations in the COL3A1 gene
that encodes type III collagen include missense mutations
(MIS) and haploinsufﬁciency (HI) mutations. The aim is
to describe the outcomes of vEDS patients based on
genotype.
